WB, IP
H M R Mk
Endogenous
55
Rabbit IgG
#Q9NYB0
54386
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the carboxy terminus of human TERF2IP protein.
Background
Telomeric repeat-binding factor 2-interacting protein (TERF2IP, also known as RAP1) is a component of the Shelterin Complex, a multi-protein complex that binds and organizes telomeres into T-loop structures to prevent them from being recognized by the cell as DNA double stranded breaks (1,2). The Shelterin Complex is composed of TERF2IP, TIN2 and TPP2 proteins, in addition to three DNA binding proteins that function to recruit the complex to telomeres: TRF1 and TRF2 bind double-stranded TTAGGG repeats found at telomeres, while the POT1 protein binds single-stranded TTAGGG repeats found at the very end of the telomeres (2). Together, these proteins function to protect telomeres and ensure proper replication and processing of chromosome ends. Recent studies have shown that TERF2IP is dispensable for maintenance of telomere length, organization of telomeric chromatin, and regulation of telomeric transcription (3,4). However, TERF2IP is required for inhibition of homology-directed repair (HDR), which can create undesirable telomeric sister chromatid exchange (3,4). In addition to its role in telomere maintenance, TERF2IP is also found in the cytoplasm, where it functions as an IκB kinase (IKK) adaptor protein and regulates NF-κB-dependent gene expression (5). TERF2IP forms a complex with IKKs and is critical for proper recruitment of IKKs to and activation of the p65 subunit of NF-κB. Elevated levels of TERF2IP have been found in breast cancer cells with NF-κB hyperactivity, and knockdown of TERF2IP sensitizes these cells to apoptosis, further identifying TERF2IP as a potential cancer therapeutic target (5).
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.